» Articles » PMID: 20564406

Selecting an Optimal Staging System for Hepatocellular Carcinoma: Comparison of 5 Currently Used Prognostic Models

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2010 Jun 22
PMID 20564406
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Selecting an appropriate staging system is crucial to predict the outcome of patients with hepatocellular carcinoma (HCC). The optimal prognostic model for HCC is under intense debate. This study investigated the prognostic ability of the 5 currently used staging systems, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Japan Integrated Scoring (JIS) system, tumor-node-metastasis (TNM), and Tokyo score, for HCC.

Methods: Between 2002 and 2008, 1713 prospectively enrolled HCC patients were compared for their long-term survival by using the Akaike information criterion (AIC) according to the staging or scoring methods of these 5 models.

Results: The mean and median follow-up duration was 18 and 14 months, respectively. Among all patients, the CLIP staging system had the lowest AIC value in comparison with other systems in the Cox proportional hazards model, followed by the Tokyo score, JIS score, BCLC staging system, and TNM staging system. Patients undergoing curative treatment had a significantly better survival in comparison with patients undergoing noncurative treatment (P < .001). When the predictive accuracy of the staging systems was analyzed according to treatment strategy, the CLIP staging system had the lowest AIC value and remained the best prognostic model in patients undergoing curative (801 patients) and noncurative (912 patients) treatment.

Conclusions: The CLIP staging system is the best long-term prognostic model for HCC in a cohort of patient with early to advanced stage of HCC. Its predictive accuracy is independent of the treatment strategy. Selecting an optimal staging system is helpful in improving the design of future clinical trials.

Citing Articles

A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.

Zeng Q, Zhou Z, Zhang J, Cai R, Yang H, Chen P BMC Cancer. 2025; 25(1):112.

PMID: 39838301 PMC: 11752828. DOI: 10.1186/s12885-024-13390-4.


Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.

Chen W, Shu K, Cai C, Ding J, Zhang X, Zhang W Biosci Rep. 2023; 43(9).

PMID: 37584192 PMC: 10500227. DOI: 10.1042/BSR20230634.


G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.

Luo Y, Wang Z, Xiao S, Li R, Jiang X Dis Markers. 2022; 2022:2628879.

PMID: 35769816 PMC: 9236775. DOI: 10.1155/2022/2628879.


Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for Barcelona-Clinic Liver Cancer (BCLC) A hepatocellular carcinoma: a meta-analysis.

Wang W, Hou S, Zhong Z, Ni J, Jiang X, Chen D J Interv Med. 2022; 1(1):49-57.

PMID: 35586344 PMC: 8607463. DOI: 10.19779/j.cnki.2096-3602.2018.01.10.


Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

Greten T, Abou-Alfa G, Cheng A, Duffy A, El-Khoueiry A, Finn R J Immunother Cancer. 2021; 9(9).

PMID: 34518290 PMC: 8438858. DOI: 10.1136/jitc-2021-002794.